Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period

Janssen (J&J Innovative Medicine)

Status: Completed

Conditions: Gastroesophageal Reflux; Pharyngeal Diseases

Treatments: Drug: Rabeprazole Sodium

Study type: Observational

Funder types: Industry

Identifiers

NCT00614536

CR014812

Details and patient eligibility

About

The purpose of this observational study is to examine RSI (Reflux Symptom Index) and RFS (Reflux Finding Score) by treatment period before and after rabeprazole treatment in LaryngoPharyngeal Reflux Disease(LPRD) patients.

Full description

This clinical study is a multicenter, open-label, prospective, observational study of outpatients who visit the department of otolaryngology (branch of medicine that deals with diagnosis and treatment of diseases of the ear, nose, and throat) under routine practice. This study will examine RSI (Reflux Symptom Index) and RFS (Reflux Finding Score) by treatment period (before and after rabeprazole treatment) in patients with LaryngoPharyngeal Reflux Disease(LPRD). Among the patients who visit the department of otolaryngology with suspicious laryngopharyngeal reflux, those needing rabeprazole sodium treatment according to the doctor's discretion are eligible for enrollment. This study will explore the correlation between RSI and RFS and will examine major reflux symptoms and types of lesions, to find the most reliable factors in diagnosing LPRD and judging therapeutic effectiveness of treatments. LPRD is a disease with various symptoms and causes lesions by exposing the upper respiratory system to gastric acid and stomach contents. RSI and RFS can be used to diagnose LPRD in a relatively objective manner by scoring items of symptoms and lesions particular to LPRD. Evaluations will be performed four times from baseline to week 12. Observational Study - one tablet of rabeprazole 10 mg or 20 mg once daily for 12 weeks

Enrollment: 1,142 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who visit the department of otolaryngology with suspicious laryngopharyngeal reflux
• Patients who need rabeprazole treatment according to the doctor's discretion
• Patients who have signed an informed consent document indicating that they understand the purpose of and procedures required for the observational study and they agree to provide their information

Exclusion criteria

• Patients who took rabeprazole within the past one month
• Patients who are hypersensitive to any of rabeprazole or benzimidazole
• Patients with severe hepatic impairment
• Pregnant or lactating women

Trial design

1,142 participants in 1 patient group

001

Treatment:

Drug: Rabeprazole Sodium